Networks

NIAID participates in or funds many different consortia, clinical trial programs, networks, and research collaborations that help to move science forward. These are listed here, with new ones added all the time. Use the Search by Keyword field to narrow your search.

Showing results filtered by:

In 2013, NIAID launched the Antibacterial Resistance Leadership Group (ARLG), a major clinical effort to address antibacterial resistance (AR).

The National Biocontainment Laboratories (NBLs) and Regional Biocontainment Laboratories (RBLs) provide BSL4/3/2 and BSL3/2 biocontainment facilities, respectively, for research on biodefense and emerging infectious disease agents.

The Bioinformatics Resource Centers (BRCs) for Infectious Diseases program was initiated in 2004 with the main objective of collecting, archiving, updating, and integrating a variety of research data and providing such information through user friendly interfaces and computational analysis tools to be made freely available to the scientific community.

The National Institute of Allergy and Infectious Diseases (NIAID) Centers of Excellence for Influenza Research and Surveillance (CEIRS) program is an integrated network of centers designed to bring together multidisciplinary teams of researchers that perform surveillance related research integrated with research on host immune response, viral pathogenesis, and the factors that control the emerg

In 2014, NIAID established the Centers of Excellence for Translational Research (CETR) program. Supported translational activities will range from very early discovery-based efforts to late-stage preclinical development.

The Functional Genomics Program for understanding the functions of uncharacterized genes in infectious disease pathogens aims to generate experimental data to determine the biochemical function(s) of hypothetical genes, unknown open reading frames, and noncoding RNAs.

The NIAID Genomic Centers for Infectious Diseases (GCID) provide insights into the biology of microbes, their role in pathogenesis, and their interactions with the host, including the microbiome, by supporting a diverse set of genomic capabilities, such as next-generation sequencing and related genomic technologies.

 The ICEMRS are a global network of independent research centers in malaria-endemic settings, established by NIAID to provide the knowledge, tools, and evidence-based strategies crucial to understanding, controlling, and, ultimately, preventing malaria.

The Structural Genomics Centers for Infectious Diseases (SGCID) apply state-of-the-art high-throughput technologies and methodologies to experimentally characterize the three dimensional (3-D) atomic structure of proteins or other molecules that play an important biological role in human pathogens and infectious diseases, especially those in the

The NIAID/Division of Microbiology and Infectious Diseases (DMID) Systems Biology Consortium for Infectious Diseases is a group of interdisciplinary scientists that bridge disparate scientific disciplines including microbiology, immunology, infectious diseases, microbiome, mathematics, physics, bioinformatics, computational biology, machine learning, statistical methods, and mathematical modeli

The Trans-NIH Microbiome Working Group (TMWG) was established in 2012 by Dr. Lita Proctor (NHGRI) to provide a forum for coordinating NIH extramural research activities related to the human microbiome. TMWG membership is open to all extramural program staff from ICs with an interest in the human microbiome. The TMWG meets monthly.

NIAID awarded the Tropical Medicine Research Centers (TMRCs) in 1991 to establish international research sites in disease-endemic countries. The program was renewed in 2017, with the funding of seven Centers (five new Centers and two renewals).

First established in 1994, the Tuberculosis Research Units Network (TBRU-N) integrates scientific and clinical research disciplines to study aspects of human TB in endemic countries. The Network is comprised of four multi-project awards to study TB latency and persistence and their relation to active TB disease in humans.

The Vaccine and Treatment Evaluation Units (VTEUs) have played a key role in NIAID’s effort to develop new and improved vaccines and therapies against infectious diseases for over four decades. They have conducted hundreds of clinical trials, many of which have contributed to vaccine licensure.